BioVendor Group NGS

fastGEN MSI Kit

A comprehensive insight into the tumour‘s molecular profile

Our advanced next-generation sequencing (NGS) technology, fastGEN, enables rapid and accurate detection of microsatellite instability (MSI) in tumor tissues. Library preparation requires DNA isolated solely from tumor tissue, with a workflow suitable for FFPE samples and tissues with low tumor cell content. A key advantage of fastGEN is that the analysis of MSI status does not require matching normal tissue for parallel evaluation.

5 reasons why fastGEN MSI Kit worths attention

High accuracy and sensitivity

NGS enables the detection of even subtle DNA changes and allows the analysis of a wide range of microsatellite sequences.

Targeted therapy

The fastGEN MSI test covers a wide range of MSI loci, providing a comprehensive view of the tumour’s molecular profile which is essential for the selection of targeted therapy and immunotherapy.

MSI status determined without normal tissue

Does not require matching normal tissue for parallel evaluation.

Seamless laboratory integration

Its straightforward and efficient workflow and the ability to process multiple samples simultaneously save time and analysis costs.

Efficiency with low-quality samples

The technology does not require high DNA concentrations, making it ideal for FFPE samples and those with a low tumour cell content.

Discover fastGEN MSI Kit on our website.

Microsatellite instability: A key biomarker for diagnosis and personalized treatment

Microsatellite instability arises due to defects in the DNA mismatch repair (MMR) system, leading to changes in microsatellite DNA sequences – short, repetitive nucleotide sequences crucial for genetic stability. Disruption of these sequences is associated with serious diseases, including colorectal and endometrial cancers, and is a hallmark of Lynch syndrome.

MSI serves as an essential biomarker for diagnosis, predicting disease progression, and selecting optimal treatment strategies. Tumours with high microsatellite instability (MSI-H) often respond well to immunotherapy, such as PD-1/PD-L1 inhibitors, paving the way for personalized treatment options for patients.

fastGEN modul in GENOVESA software for your service

- User-friendliness
- Automatized bioinformatic analysis of NGS data
- Advanced quality control of sequencing data
- Local clinical database
- Visualization of NGS data
- Data sharing between clinics
- Clinical report generation
- Custom baseline creation



Contact us

Iveta Tóthová, Ph.D.
Product & Scientific Manager
tothova@biovendor-mdx.com

PRODUCER:

BioVendor R&D®

DISTRIBUTOR:

BioVendor MDx

BioVendor MDx a.s.
Karásek 1767/1, 621 00 Brno
Czech Republic
info@biovendor-mdx.com
www.biovendor.group

FOLLOW US

BIOVENDOR.GROUP